M

Merck

Makes medicines, vaccines and animal treatments

Principal Scientist Multiscale Separations Team Lead

Full-TimeUpdated Deadline 10/30/26
$156.9k - $247k+ Annual bonus + Long-term incentive
Expert
Master's, PhD
Rahway, NJ, USA
In PersonRole is located in Rahway, New Jersey; travel requirements are 10%.
Biology & BiotechBioprocess & Biomanufacturing
H1B Sponsorship Available

About the job

Requirements
  • A Ph.D. in Chemistry, Analytical Chemistry, Pharmaceutical Sciences, Chemical Engineering, or a related scientific discipline and at least 8 years of relevant industrial experience in pharmaceutical, biotechnology, or related drug development and research; or an M.S. in one of those disciplines and 10–12 years of relevant industrial experience in a pharmaceutical, biotechnology, or related drug discovery research environment.
  • Extensive experience in chromatographic purification and analytical separations supporting drug development programs, including HPLC, uHPLC, LCMS, SFC, and preparative chromatography technologies.
  • Working knowledge of orthogonal detection technologies, including PDA, multi-angle light scattering, and charged aerosol detection.
  • Hands-on experience delivering purification solutions across scales from micrograms to kilograms, enabling translation from early-stage experimentation through larger-scale execution.
  • Experience supporting multiple therapeutic modalities, including small molecules, peptides, adjuvants, and other emerging modalities.
  • Ability to provide scientific leadership, influence technical direction, and deliver results through a laboratory-based scientific capability, including leadership in chromatography, separation sciences, and analytical chemistry.
  • Experience implementing new technologies, laboratory informatics platforms, LIMS solutions, automation-enabled purification workflows, digital workflows, instrumentation, and process improvements.
  • Experience mentoring and developing scientific staff.
  • Commitment to safety, quality, and operational excellence.
  • Required skills include analytical method development, assay development, bioanalytical analysis, chromatographic techniques, clinical judgment, cross-functional teamwork, dosage forms, ethical compliance, liquid chromatography, matrix management, mentoring staff, method validation, personal initiative, stability testing, and technical writing.
Responsibilities
  • Provide scientific leadership and contribute to purification and analytical activities that enable the development pipeline as a recognized subject matter expert in purification and separation sciences.
  • Provide technical leadership and expertise in chromatographic purification, analytical separations, impurity isolation, and related technologies, and guide resolution of complex scientific and operational challenges.
  • Foster scientific excellence, operational efficiency, safety, and quality throughout laboratory operations.
  • Partner with DSCS digital technologies to drive and implement innovative technologies, laboratory informatics platforms, automation-enabled purification workflows, and digital capabilities that improve Separation Sciences capabilities.
  • Establish best practices, drive continuous improvement initiatives, and contribute to capability roadmaps aligned with CMC needs.
  • Partner with the Director of Separation Sciences to identify, recruit, mentor, and develop scientists and laboratory staff, building technical expertise and leadership capability across the organization.
  • Foster a collaborative, inclusive, and high-performing environment that supports employee development, succession planning, and scientific excellence.
  • Partner with Process Chemistry, Pharmaceutical Analytical Sciences, Automation, Informatics, IT, and other research functions to support project progression and capability development.
  • Serve as a scientific partner to project teams, contributing purification and analytical expertise to project strategy and departmental initiatives.
  • Partner in laboratory operations, instrumentation strategy, capital planning, and implementation of automation and digital solutions that improve scientific productivity.
  • Partner with Facilities, Procurement, Engineering, IT, and external vendors to ensure reliable laboratory operations, regulatory compliance, and continued capability advancement.
  • Maintain awareness of emerging technologies and scientific advances in separation sciences and chromatography; contribute to the company's scientific reputation through publications, presentations, collaborations, and external engagement.
Desired Qualifications
  • Experience leading cross-functional and cross-site scientific initiatives, deploying capabilities, transferring technology, and collaborating across purification networks, including internal and external CDMOs, scientific disciplines, and research organizations.
  • Experience in mass spectrometry and its application in MS-directed chromatographic purification.
  • Experience partnering with IT, Informatics, Automation, Facilities, Procurement, and external vendors to develop and advance scientific capabilities.
  • Experience with laboratory capital planning, laboratory build-out, infrastructure strategy, or management of scientific instrumentation portfolios.
  • Publications, presentations, patents, or other evidence of external scientific engagement and professional visibility.
  • Pharmaceutical cGMP experience.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 28th, 2026
Merck earnings preview: flat Q3 revenue expected after $16.61B last quarter

Merck (NYSE:MRK) reports third-quarter earnings on Thursday before market open. It is the first of its peers to report this season. Analysts expect revenue to be flat year on year, slowing from a 3.7% rise in the same quarter last year. Estimates have largely held steady over the past 30 days. Last quarter, Merck beat revenue expectations with $16.61 billion, up 5.1% year on year. It also beat analysts' earnings per share estimates but missed full-year EPS guidance estimates. Pharmaceutical shares have risen 3.6% on average over the last month. Merck is down 4.5% over the same period.

Yahoo Finance
Oct 28th, 2026
Merck's oncology wins lift outlook, but 110x P/E clouds its $141.82 share price

Merck (MRK) is drawing investor attention after oncology trials showed meaningful survival benefits for KEYTRUDA, sacituzumab tirumotecan, and a melanoma vaccine developed with Moderna. The shares closed at $141.82, down 4.37% over seven days and 4.68% over 30 days. They are still up 33.23% this year and 67.74% over one year in total shareholder return. A popular narrative puts fair value at $159.76, making the stock 11% undervalued. Merck plans more than 20 new growth drivers, with management pointing to over $70 billion in mid-2030s revenue potential to offset the KEYTRUDA loss of exclusivity. Valuation remains contested. Merck trades at 110.3 times earnings, against a fair ratio of 50.2, a US pharmaceuticals average of 15.7, and peers at 33.9. Its profit margin is 4.8%.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Financial News
Oct 24th, 2026
Moderna cancer vaccine data confirms 42% recurrence cut.

Moderna cancer vaccine data confirms 42% recurrence cut. Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings in MRNA shares. Moderna cancer vaccine data showed a 42% reduction in melanoma recurrence or death, the company and partner Merck confirmed on 22 October 2026, two days after an embargo breach forced them to release results early. Moderna (NASDAQ: MRNA) shares fell as much as 26% intraday to $181.14 when the Phase 3 trial data leaked online, before closing down 17.6% that day, according to CNBC. What the Moderna cancer vaccine data showed. The Phase 3 INTerpath-001 trial tested intismeran autogene, an individualised mRNA therapy, alongside Merck's Keytruda (pembrolizumab) in patients with completely resected stage IIB-IV melanoma. The combination cut the risk of recurrence or death by 42% versus Keytruda alone, a hazard ratio of 0.58, with a two-sided p-value below 0.001, according to Merck's own release of the figures. Median follow-up stood at 24.6 months, roughly the two years referenced when Moderna first flagged a positive outcome. A pre-specified sensitivity analysis covering the period after the six-month immunisation course found an even larger effect, with a hazard ratio of 0.42. Distant metastasis-free survival also improved, with the combination cutting the risk of distant spread or death by 38%, Merck's release showed. Overall survival data remain immature, leaving the durability of the benefit as the open question for the therapy's long-term value. An embargo breach, not a trial failure. Moderna first disclosed in August 2026 that INTerpath-001 had met its recurrence-free and distant-metastasis-free survival endpoints, without releasing the underlying numbers. The detailed data was due to be unveiled at the European Society for Medical Oncology's Presidential Symposium on 24 October. Instead, ESMO confirmed the embargo on the trial's late-breaking abstract had been breached, forcing the companies to issue their results two days ahead of schedule, as ESMO itself stated. Stock swings outpace the clinical story. The gap between the intraday plunge and the eventual close is the clearest sign that trading mechanics, not the science, drove the sharpest moves. A result investors had largely expected to be positive instead triggered a sell-off because nobody had the detail, and algorithmic and retail flows reacted to a leak rather than a verified release. By 23 October, Moderna shares had settled at $201.34, down 1.79% on the day but still up 6.59% over the prior 20 trading sessions, against a 20-day range of $182.07 to $252.95, according to consolidated US exchange data. FINRA short-sale data showed no surge in bearish positioning around the leak, with the daily short-sale ratio holding in a tight 0.60 to 0.71 band through the episode, suggesting the swings reflected confused trading rather than an organised bet against the stock. A loss-making pipeline bet. The volatility lands against a backdrop of persistent losses as Moderna leans on cancer and rare-disease programmes to offset collapsing Covid-19 vaccine demand. The company reported a net loss of $782m on revenue of just $145m in the second quarter of 2026, following a $1.343bn loss in the first quarter, according to filings with the SEC. Quarterly revenue has swung sharply between periods, from $1.016bn in the third quarter of 2025 - driven by seasonal vaccine deliveries - to $389m in the first quarter of 2026, underscoring how dependent the share price has become on pipeline news flow rather than product sales. Intismeran autogene, partnered with Merck since 2016, is viewed inside both companies as the clearest near-term route to diversifying away from that vaccine dependency. Regulatory filings based on the INTerpath-001 dataset are expected to follow the Presidential Symposium presentation, with overall survival data - still immature - likely to shape how regulators and oncologists weigh the therapy's long-term case. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.

The Pharma Letter
Oct 24th, 2026
Regeneron's Justin Holko: building a global oncology business with a lean, US-accountable core.

Regeneron's Justin Holko: building a global oncology business with a lean, US-accountable core. 22 October 2026 Senior vice president tells The Pharma Letter how the US biotech major challenged the big pharma playbook, pairing a central global strategy with local market autonomy as it scaled its PD-1 inhibitor into a near-$2 billion-a-year product. Regeneron Pharmaceuticals' (Nasdaq: REGN) Justin Holko (pictured below), senior vice president and head of the global oncology commercial business unit, joined the Tarrytown, New York-based company in 2019 after 19 years at US pharma giant Merck & Co (NYSE: MRK). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 13 October 2026 22 September 2026 6 October 2026 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 24 October 2026 23 October 2026 Company spotlight. A clinical-stage Swiss ophthalmology biotech using its proprietary OPTIREACH drop technology to deliver biologics and small molecules to the back of the eye - a route that has until now required intravitreal injection. More features in biotechnology. 24 October 2026 23 October 2026